Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 6/2010

01-06-2010 | Original Article

Sleep quality after initial chemotherapy for breast cancer

Authors: Susan L. Beck, Ann M. Berger, Andrea M. Barsevick, Bob Wong, Katie A. Stewart, William N. Dudley

Published in: Supportive Care in Cancer | Issue 6/2010

Login to get access

Abstract

Goals of work

The goal of this study is to characterize sleep quality and quantity prior to and in the first three nights after initial chemotherapy for breast cancer.

Materials and methods

This study makes use of secondary analysis of data from two separate randomized clinical trials (RCT) of behavioral interventions to improve fatigue and sleep. Patients came from two comprehensive cancer centers, three clinical cancer centers, and 10 community clinics in five states. Participants were women with stage I–IIIA breast cancer treated with anthracycline and/or cyclophosphamide-based regimens.

Main results

Baseline data from each RCT were used in the analysis. Sixty-five percent of women self-reported poor sleep in the month preceding chemotherapy using the Pittsburgh Sleep Quality Index (PSQI) score >5. Three nights of actigraphy data indicated a wide range of sleep experience with an average of 10 awakenings and time (minutes) awake after sleep onset (WASO-M) averaging 61 min per night. The first night’s sleep was the worst. There was no statistically significant relationship between self-reported poor sleep and sleep measures obtained by actigraphy. Women with poor sleep at baseline (global PSQI >5) had significantly lower (p < 0.001) physical (PCS) and mental (MCS) health status. However, neither the PCS nor MCS was associated with any of the average actigraphy sleep parameters or night 1 parameters in the aggregated sample. Increasing age was also associated with poorer sleep.

Conclusions

A high percent of women with breast cancer begin chemotherapy with disturbed sleep and the initial nights after chemotherapy are characterized by sleep fragmentation that disrupts sleep maintenance. Interventions should focus on strategies to decrease the number and duration of night awakenings. Further research is needed to identify predictors of poor sleep during this time.
Literature
1.
Berger AM, Parker KP, Young-McCaughan S, Mallory GA, Barsevick AM, Beck SL et al (2005) Sleep wake disturbances in people with cancer and their caregivers: State of the science. Oncol Nurs Forum 32:E98–E1126CrossRefPubMed
2.
Savard J, Morin CM (2001) Insomnia in the context of cancer: a review of a neglected problem. J Clin Oncol 19:895–908PubMed
3.
Lee K, Cho M, Miaskowski C, Dodd M (2004) Impaired sleep and rhythms in persons with cancer. Sleep Med Rev 8:199–212CrossRefPubMed
4.
Clark J, Cunningham M, McMillan S, Vena C, Parker K (2004) Sleep-wake disturbances in people with cancer part ii: evaluating the evidence for clinical decision making. Oncol Nurs Forum 31:747–771CrossRefPubMed
5.
Savard J, Simard S, Blanchet J, Ivers H, Morin CM (2001) Prevalence, clinical characteristics, and risk factors for insomnia in the context of breast cancer. Sleep 24:583–590PubMed
6.
Carpenter JS, Andrykowski MA (1998) Psychometric evaluation of the Pittsburgh Sleep Quality Index. J Psychosom Res 45:5–13CrossRefPubMed
7.
Berger AM, Farr L (1999) The influence of daytime inactivity and nighttime restlessness on cancer-related fatigue. Oncol Nurs Forum 26:1663–1671PubMed
8.
Berger AM, Higginbotham P (2000) Correlates of fatigue during and following adjuvant breast cancer chemotherapy: a pilot study. Oncol Nurs Forum 27:1443–1448PubMed
9.
Broeckel JA, Jacobsen PB, Horton J, Balducci L, Lyman GH (1998) Characteristics and correlates of fatigue after adjuvant chemotherapy for breast cancer. J Clin Oncol 16:1689–1696PubMed
10.
Redeker NS, Lev EL, Ruggiero J (2000) Insomnia, fatigue, anxiety, depression, and quality of life of cancer patients undergoing chemotherapy. Sch Inq Nurs Pract 14:275–298PubMed
11.
Berger AM (1998) Patterns of fatigue and activity and rest during adjuvant breast cancer chemotherapy. Oncol Nurs Forum 25:51–62PubMed
12.
Berger AM, VonEssen S, Khun BR, Piper BF, Farr L, Agrawal S et al (2002) Feasibilty of a sleep intervention during adjuvant breast cancer chemotherapy. Oncol Nurs Forum 29:1431–1441CrossRefPubMed
13.
Payne J, Piper B, Rabinowitz I, Zimmerman B (2006) Biomarkers, fatigue, sleep, and depressive symptoms in women with breast cancer: a pilot study. Oncol Nurs Forum 33:775–783CrossRefPubMed
14.
15.
16.
17.
18.
19.
20.
Hauri P, Wisbey J (1994) Actigraphy and insomnia: a closer look. Part 2. Sleep: 408–410.
21.
Jean-Louis G, von Gizycki H, Zizi F, Spielman A, Hauri P, Taub H (1997) The actigraph data analysis software: II. A novel approach to scoring and interpreting sleep-wake activity. Percept Mot Skills 85:219–226CrossRefPubMed
22.
Ancoli-Israel S, Cole R, Alessi C, Chambers M, Moorcroft W, Pollak CP (2003) The role of actigraphy in the study of sleep and circadian rhythms. Sleep 26:342–392PubMed
23.
Blackwell T, Ancoli-Israel S, Gehrman PR, Schneider JL, Pedula KL, Stone KL (2005) Actigraphy scoring reliability in the study of osteoporotic fractures. Sleep 28:1599–1605PubMed
24.
Lichstein KL, Stone KC, Donaldson J, Nau SD, Soeffing JP, Murray D et al (2006) Actigraphy validation with insomnia. Sleep 29:232–239PubMed
25.
Ware JE Jr, Snow KK, Kosinski M, Gandek B (1993) SF-36 health survey manual and interpretation guide. The Health Institute, New England Medical Center, Boston
26.
Tsai C, Bayliss MS, Ware JE (1997) SF-36 health survey annotated bibliography, 2nd edn. Heath Assessment Lab, New England Medical Centre, Boston
27.
Ware JE, Kosinski M (2007) SF-36 physical and mental health summaerty scales: a manual for users of version 1, 2nd edn. Quality Metric, Lincoln
28.
29.
30.
31.
32.
Barker LE, Luman ET, McCauley MM, Chu SY (2002) Assessing equivalence: an alternative to the use of difference tests for measuring disparities in vaccination coverage. Am J Epidemiol 156:1056–1061. doi:10.​1093/​aje/​kwf149 CrossRefPubMed
33.
Schuirmann DJ (1987) A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 15:657–680. doi:10.​1007/​BF01068419 CrossRefPubMed
34.
Lineberger MD, Carney CE, Edinger JD, Means MK (2006) Defining insomnia: quantitative criteria for insomnia severity and frequency. Sleep 29:479–485PubMed
35.
36.
37.
Berger AM, Sankaranarayanan J, Watanabe-Galloway S (2007) Current methodological approaches to the study of sleep disturbances and quality of life in adults with cancer: a systematic review. Psychooncology 16:401–420. doi:10.​1002/​pon.​1079 CrossRefPubMed
38.
39.
Buysse DJ, Hall ML, Strollo PJ, Kamarck TW, Owens J, Lee L et al (2008) Relationships between the Pittsburgh Sleep Quality Index (PSQI), Epworth Sleepiness Scale (ESS), and clinical/polysomnographic measures in a community sample. J Clin Sleep Med 4:563–571PubMed
40.
Espie CA, Fleming L, Cassidy J, Samuel L, Taylor LM, White CA et al (2008) Randomized controlled clinical effectiveness trial of cognitive behavior therapy compared with treatment as usual for persistent insomnia in patients with cancer. J Clin Oncol 26:4651–4658. doi:10.​1200/​JCO.​2007.​13.​9006 CrossRefPubMed
41.
Vitiello MV, Larsen LH, Moe KE (2004) Age-related sleep change: gender and estrogen effects on the subjective-objective sleep quality relationships of healthy, noncomplaining older men and women. J Psychosom Res 56:503–510. doi:10.​1016/​S0022-3999(04)00023-6 CrossRefPubMed
42.
43.
Ohayon MM, Carskadon MA, Guilleminault C, Vitiello MV (2004) Meta-analysis of quantitative sleep parameters from childhood to old age in healthy individuals: developing normative sleep values across the human lifespan. Sleep 27:1255–1273PubMed
44.
Metadata
Title
Sleep quality after initial chemotherapy for breast cancer
Authors
Susan L. Beck
Ann M. Berger
Andrea M. Barsevick
Bob Wong
Katie A. Stewart
William N. Dudley
Publication date
01-06-2010
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 6/2010
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-009-0662-y

Other articles of this Issue 6/2010

Supportive Care in Cancer 6/2010 Go to the issue

Original Article

Is bra discomfort a barrier to exercise for breast cancer patients?

Original Article

Evaluation of analgesic effect and safety of fentanyl transdermal patch for cancer pain as the first line

Original Article

Impact of caregivers’ unmet needs for supportive care on quality of terminal cancer care delivered and caregiver’s workforce performance

Original Article

Nutritional support for head and neck cancer patients receiving radiotherapy: a systematic review

Original Article

Perceived barriers to physical activity for colorectal cancer survivors

Original Article

Effects of the enteral administration of Bifidobacterium breve on patients undergoing chemotherapy for pediatric malignancies
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits